{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T12:46:25Z","timestamp":1784119585315,"version":"3.55.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2018,7,16]],"date-time":"2018-07-16T00:00:00Z","timestamp":1531699200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Moorfields Eye Charity"},{"name":"Birmingham Eye Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1038\/s41433-018-0151-y","type":"journal-article","created":{"date-parts":[[2018,7,16]],"date-time":"2018-07-16T13:22:29Z","timestamp":1531747349000},"page":"1752-1759","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Retinopathy of prematurity in the United Kingdom: retreatment rates, visual and structural 1-year outcomes"],"prefix":"10.1038","volume":"32","author":[{"name":"UK Retinopathy of Prematurity Special Interest Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian GW","family":"Adams","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0935-3713","authenticated-orcid":false,"given":"Catey","family":"Bunce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucilla","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vernon","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aravind","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annegret H.","family":"Dahlmann-Noor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,16]]},"reference":[{"key":"151_CR1","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","volume":"121","author":"Early Treatment For Retinopathy Of Prematurity Cooperative G.","year":"2003","unstructured":"Early Treatment For Retinopathy Of Prematurity Cooperative G. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol. 2003;121:1684\u201394.","journal-title":"Arch Ophthalmol"},{"key":"151_CR2","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.ophtha.2008.09.035","volume":"116","author":"BV Davitt","year":"2009","unstructured":"Davitt BV, Dobson V, Quinn GE, Hardy RJ, Tung B, Good WV, et al. Astigmatism in the Early treatment for retinopathy of prematurity study: findings to 3 years of age. Ophthalmology. 2009;116:332\u20139.","journal-title":"Ophthalmology"},{"key":"151_CR3","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1136\/bjo.82.11.1265","volume":"82","author":"M Holmstrom","year":"1998","unstructured":"Holmstrom M, el Azazi M, Kugelberg U. Ophthalmological long-term follow up of preterm infants: a population based, prospective study of the refraction and its development. Br J Ophthalmol. 1998;82:1265\u201371.","journal-title":"Br J Ophthalmol"},{"key":"151_CR4","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1136\/bjo.86.9.1035","volume":"86","author":"KJ Saunders","year":"2002","unstructured":"Saunders KJ, McCulloch DL, Shepherd AJ, Wilkinson AG. Emmetropisation following preterm birth. Br J Ophthalmol. 2002;86:1035\u201340.","journal-title":"Br J Ophthalmol"},{"key":"151_CR5","doi-asserted-by":"publisher","first-page":"3782","DOI":"10.1167\/iovs.11-8727","volume":"53","author":"L Deng","year":"2012","unstructured":"Deng L, Gwiazda JE. Anisometropia in children from infancy to 15 years. Invest Ophthalmol Vis Sci. 2012;53:3782\u20137.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"151_CR6","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1007374","volume":"364","author":"HA Mintz-Hittner","year":"2011","unstructured":"Mintz-Hittner HA, Kennedy KA, Chuang AZ. Group B-RC Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Eng J Med. 2011;364:603\u201315.","journal-title":"N Eng J Med"},{"key":"151_CR7","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.3928\/23258160-20161130-03","volume":"47","author":"T Chuluunbat","year":"2016","unstructured":"Chuluunbat T, Chan RV, Wang NK, Lien R, Chen YP, Chao AN, et al. Nonresponse and recurrence of retinopathy of prematurity after intravitreal ranibizumab treatment. Ophthalmic Surg Lasers Imaging Retina. 2016;47:1095\u2013105.","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"151_CR8","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1001\/jamaophthalmol.2014.2772","volume":"132","author":"MM Geloneck","year":"2014","unstructured":"Geloneck MM, Chuang AZ, Clark WL, Hunt MG, Norman AA, Packwood EA, et al. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmol. 2014;132:1327\u201333.","journal-title":"JAMA Ophthalmol"},{"key":"151_CR9","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/j.ophtha.2016.04.028","volume":"123","author":"HA Mintz-Hittner","year":"2016","unstructured":"Mintz-Hittner HA, Geloneck MM, Chuang AZ. Clinical managemen of recurrent retinopathy of prematurity after intravitreal bevacizumab monotherapy. Ophthalmology. 2016;123:1845\u201355.","journal-title":"Ophthalmology"},{"key":"151_CR10","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1097\/IAE.0000000000001125","volume":"37","author":"JM Yoon","year":"2017","unstructured":"Yoon JM, Shin DH, Kim SJ, Ham DI, Kang SW, Chang YS, et al. Outcomes after laser versus combined laser and bevacizumab treatment for type 1 retinopathy of prematurity in zone I. Retina. 2017;37:88\u201396.","journal-title":"Retina"},{"key":"151_CR11","first-page":"1","volume":"42","author":"M Gunay","year":"2016","unstructured":"Gunay M, Sukgen EA, Celik G, Kocluk Y. Comparison of bevacizumab, ranibizumab, and laser photocoagulation in the treatment of retinopathy of prematurity in Turkey. Curr Eye Res. 2016;42:1\u20138.","journal-title":"Curr Eye Res"},{"key":"151_CR12","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.ophtha.2014.12.017","volume":"122","author":"CK Hwang","year":"2015","unstructured":"Hwang CK, Hubbard GB, Hutchinson AK, Lambert SR. Outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity: a 5-year retrospective analysis. Ophthalmology. 2015;122:1008\u201315.","journal-title":"Ophthalmology"},{"key":"151_CR13","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1111\/aos.12266","volume":"92","author":"BC Harder","year":"2014","unstructured":"Harder BC, von Baltz S, Jonas JB, Schlichtenbrede FC. Intravitreal low-dosage bevacizumab for retinopathy of prematurity. Acta Ophthalmol (Copenh). 2014;92:577\u201381.","journal-title":"Acta Ophthalmol (Copenh)"},{"key":"151_CR14","first-page":"355","volume":"109","author":"N O\u2019Keeffe","year":"2016","unstructured":"O\u2019Keeffe N, Murphy J, O\u2019Keefe M, Lanigan B. Bevacizumab compared with diode laser in stage 3 posterior retinopathy of prematurity: a 5 year follow up. Ir Med J. 2016;109:355.","journal-title":"Ir Med J"},{"key":"151_CR15","first-page":"CD009734","volume":"2","author":"MJ Sankar","year":"2016","unstructured":"Sankar MJ, Sankar J, Mehta M, Bhat V, Srinivasan R. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity. Cochrane Database Syst Rev. 2016;2:CD009734.","journal-title":"Cochrane Database Syst Rev"},{"key":"151_CR16","doi-asserted-by":"publisher","first-page":"300","DOI":"10.5935\/0004-2749.20150079","volume":"78","author":"M Gunay","year":"2015","unstructured":"Gunay M, Celik G, Gunay BO, Aktas A, Karatekin G, Ovali F. Evaluation of 2-year outcomes following intravitreal bevacizumab (IVB) for aggressive posterior retinopathy of prematurity. Arq Bras Oftalmol. 2015;78:300\u20134.","journal-title":"Arq Bras Oftalmol"},{"issue":"7","key":"151_CR17","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1080\/02713683.2016.1264607","volume":"42","author":"Emrah Utku Kabata\u015f","year":"2017","unstructured":"Kabatas EU, Kurtul BE, Altiaylik Ozer P, Kabatas N. Comparison of intravitreal bevacizumab, intravitreal ranibizumab and laser photocoagulation for treatment of type 1 retinopathy of prematurity in Turkish preterm children. Curr Eye Res. 2017;42: 1054-1058.","journal-title":"Current Eye Research"},{"key":"151_CR18","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3109\/09273972.2016.1159232","volume":"24","author":"M Gunay","year":"2016","unstructured":"Gunay M, Sekeroglu MA, Bardak H, Celik G, Esenulku CM, Hekimoglu E, et al. Evaluation of refractive errors and ocular biometric outcomes after intravitreal bevacizumab for retinopathy of prematurity. Strabismus. 2016;24:84\u201388.","journal-title":"Strabismus"},{"key":"151_CR19","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1136\/bjophthalmol-2015-307263","volume":"100","author":"G Holmstrom","year":"2016","unstructured":"Holmstrom G, Hellstrom A, Jakobsson P, Lundgren P, Tornqvist K, Wallin A. Five years of treatment for retinopathy of prematurity in Sweden: results from SWEDROP, a national quality register. Br J Ophthalmol. 2016;100:1656\u201361.","journal-title":"Br J Ophthalmol"},{"key":"151_CR20","doi-asserted-by":"publisher","first-page":"e013366","DOI":"10.1136\/bmjopen-2016-013366","volume":"7","author":"GG Adams","year":"2017","unstructured":"Adams GG, Bunce C, Xing W, Butler L, Long V, Reddy A, et al. Treatment trends for retinopathy of prematurity in the UK: active surveillance study of infants at risk. BMJ Open. 2017;7:e013366.","journal-title":"BMJ Open"},{"key":"151_CR21","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/0042-6989(94)90168-6","volume":"34","author":"TO Adoh","year":"1994","unstructured":"Adoh TO, Woodhouse JM. The Cardiff acuity test used for measuring visual acuity development in toddlers. Vision Res. 1994;34:555\u201360.","journal-title":"Vision Res"},{"key":"151_CR22","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1097\/00006324-199009000-00011","volume":"67","author":"ML Courage","year":"1990","unstructured":"Courage ML, Adams RJ. Visual acuity assessment from birth to three years using the acuity card procedure: cross-sectional and longitudinal samples. Optom Vis Sci. 1990;67:713\u20138.","journal-title":"Optom Vis Sci"},{"key":"151_CR23","first-page":"341","volume":"51","author":"P Sharma","year":"2003","unstructured":"Sharma P, Bairagi D, Sachdeva MM, Kaur K, Khokhar S, Saxena R. Comparative evaluation of Teller and Cardiff acuity tests in normals and unilateral amblyopes in under-two-year-olds. Indian J Ophthalmol. 2003;51:341\u20135.","journal-title":"Indian J Ophthalmol"},{"key":"151_CR24","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/j.ophtha.2005.03.025","volume":"112","author":"BV Davitt","year":"2005","unstructured":"Davitt BV, Dobson V, Good WV, Hardy RJ, Quinn GE, Siatkowski RM, et al. Prevalence of myopia at 9 months in infants with high-risk prethreshold retinopathy of prematurity. Ophthalmology. 2005;112:1564\u20138.","journal-title":"Ophthalmology"},{"key":"151_CR25","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/j.ophtha.2007.07.028","volume":"115","author":"GE Quinn","year":"2008","unstructured":"Quinn GE, Dobson V, Davitt BV, Hardy RJ, Tung B, Pedroza C, et al. Progression of myopia and high myopia in the early treatment for retinopathy of prematurity study: findings to 3 years of age. Ophthalmology. 2008;115:1058\u201364 e1051.","journal-title":"Ophthalmology"},{"key":"151_CR26","doi-asserted-by":"publisher","first-page":"e7961","DOI":"10.1136\/bmj.e7961","volume":"345","author":"T Moore","year":"2012","unstructured":"Moore T, Hennessy EM, Myles J, Johnson SJ, Draper ES, Costeloe KL, et al. Neurological and developmental outcome in extremely preterm children born in England in 1995 and 2006: the EPICure studies. BMJ. 2012;345:e7961.","journal-title":"BMJ"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41433-018-0151-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41433-018-0151-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41433-018-0151-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:04:41Z","timestamp":1684616681000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-018-0151-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,16]]},"references-count":26,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["151"],"URL":"https:\/\/doi.org\/10.1038\/s41433-018-0151-y","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,16]]},"assertion":[{"value":"27 September 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"This work was funded by Moorfields Eye Charity and the Birmingham Eye Foundation. There have not been any financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years and no other relationships or activities that could appear to have influenced the submitted work. The funders have not in any way influenced the study design or conduct, and the researchers are independent from the funders. All authors, external and internal, had full access to all of the data (including statistical reports and tables) in the study and can take responsibility for the integrity of the data and the accuracy of the data analysis. The lead author, AHDN, affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned have been explained.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}